Isoacteoside, a dihydroxyphenylethyl glycoside, exhibits anti‐inflammatory effects through blocking toll‐like receptor 4 dimerization
British Journal of Pharmacology2017Vol. 174(17), pp. 2880–2896
Citations Over TimeTop 10% of 2017 papers
Hongwei Gao, Yankun Cui, Naixin Kang, Xin Liu, Yanli Liu, Yue Zou, Ziyu Zhang, Xiaoran Li, Shilin Yang, Ji Li, Chunming Wang, Qiongming Xu, Xiuping Chen
Abstract
Isoacteoside blocked TLR4 dimerization, which activates the MyD88-TAK1-NF-κB/MAPK signalling cascades and TRIF pathway. Our data indicate that isoacteoside is a potential lead compound for the treatment of inflammatory diseases.
Related Papers
- → Rip1 Mediates the Trif-dependent Toll-like Receptor 3- and 4-induced NF-κB Activation but Does Not Contribute to Interferon Regulatory Factor 3 Activation(2005)336 cited
- A Toll-like receptor 3 agonist (polyI:C) elicits innate host responses in the spleen and lungs of chickens.(2012)
- → Suppression of the TRIF-dependent signaling pathway of Toll-like receptor by CDr10b in RAW264.7 macrophages(2015)6 cited
- → Yamamoto et al. Role of adapter TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-3(2004)
- Toll-like receptor adaptor proteins(2011)